2025-06-05-Jefferies-英莫德（INMD）_帝国心态_宏观不确定性；美国_非美国市场组合变化影响利润率_7页_104kb

报告摘要

Summary of Inmode Ltd (INMD) Equity Research Report

Company Overview: Inmode Ltd designs, develops, manufactures, and markets minimally invasive and non-invasive aesthetic medical products, targeting procedures like hair reduction, skin rejuvenation, and cellulite treatment. The company is headquartered in Yokneam, Israel and has a presence in the US and overseas markets.
Analyst Rating and Key Insights: The report rates INMD as HOLD with a price target of $14.00, representing a -5% discount from the current trading range of $19.85 to $13.68. Key takeaways include ongoing macro uncertainty, the impact of mixed-shifting from a usual US/Overseas split to 50/50 (FY25 sales guidance down by 4-5% due to US being the most profitable region), and tariff effects absorbing 2-3% gross margin impact. Analysts emphasize positive international strategic moves improving performance in Europe and APAC due to less market exposure.
Financial Performance and Guidance: Full-year 2025 sales guidance is $100-102MM (+15.7-18% year-over-year growth), with a forecast for two launches in 2025 (e.g., Empower platform for women's health and ophthalmology applications). InMode highlights its 15 ongoing R&D projects, releasing two per year despite regulatory hurdles, while also facing challenges like US business exposure to heightened external headwinds.
Strategic and Capital Management Considerations: The company has restructured North American management to enhance sales operations, repurchased about 30% of its shares over the past 2.5 years in a tax-efficient manner, and considers buybacks amid potential 20% dividend tax in 2025. Alternatives include prioritizing M&A or delaying decisions due to operational requirements and shareholder concerns on capital allocation. New product developments are on track for two yearly launches.
Risks and Valuation: Downside risks include economic downturns affecting procedure demand, regulatory delays, increased competition, pricing headwinds from economic sensitivity, and slower growth in core markets. Upside potential from improving macro conditions and new product launches. Valuation is based on an 8x 2026 earnings per share multiple, with a HOLD recommendation reflecting uncertainties.